Klinikum Bremen-Mitte

Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario

Abstract Tagraxofusp (TAG), a CD123-directed protein-drug conjugate, is approved in front-line and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). Multicenter real-world outcomes and the contribution of up-front consolidation post-TAG remain less defined...

Severe antipsychotic-associated gastrointestinal hypomotility: AMSP pharmacovigilance data from 333,175 psychiatric inpatients

Abstract Background Severe courses of gastrointestinal hypomotility (GIH) are rare but potentially life-threatening adverse drug reactions (ADRs) associated with antipsychotic drugs (APDs). This study aimed to investigate the frequency, clinical characteristics, and associated dr...

Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer – results from the phase II DETECT IVb trial

Abstract Background Eribulin is a non-taxane microtubule inhibitor that showed survival benefits for pretreated metastatic breast cancer (MBC) patients. Circulating tumor cells (CTCs) are a prognostic marker, but their role in predicting response to specific MBC treatments is les...

Pediatric intensive care follow-up in Germany is rarely established and highly heterogeneous: a nationwide survey of 20 PICUs

BACKGROUND: Survival after pediatric critical illness has improved substantially, but many survivors and their families experience long-term physical, neurocognitive, psychological and social sequelae, summarized as post-intensive care syndrome in pediatrics and in families. Stru...